{"id":52124,"date":"2025-12-29T11:36:49","date_gmt":"2025-12-29T03:36:49","guid":{"rendered":"https:\/\/flcube.com\/?p=52124"},"modified":"2025-12-29T11:36:51","modified_gmt":"2025-12-29T03:36:51","slug":"ndrc-expands-foreign-investment-in-healthcare-with-2025-catalogue","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52124","title":{"rendered":"NDRC Expands Foreign Investment in Healthcare with 2025 Catalogue"},"content":{"rendered":"\n

The National Development and Reform Commission (NDRC)<\/strong> issued the “Catalogue of Industries Encouraging Foreign Investment (2025 Edition)”<\/strong> , effective February\u202f1\u202f2026<\/strong>, repealing the 2022 edition. The new catalogue adds nine refined healthcare sectors<\/strong>, including novel drug development, biotech engineering, radiopharmaceuticals, and internet\u2011based healthcare services.<\/p>\n\n\n\n

Key Healthcare Additions<\/h2>\n\n\n\n
Category<\/th>Description<\/th><\/tr><\/thead>
\u2460 Novel Drugs<\/strong><\/td>Active ingredient drugs, chemically innovative drugs, quality\u2011evaluated generics, high\u2011value APIs, high\u2011end preparations, clinical shortage drugs<\/td><\/tr>
\u2461 Outsourcing Services<\/strong><\/td>CROs for drug\/medical device R&D and production<\/td><\/tr>
\u2462 Biotech Engineering<\/strong><\/td>Novel antibody drugs, multifunctional antibodies, GPCR antibodies, ADCs, recombinant protein drugs<\/td><\/tr>
\u2463 Drug Delivery<\/strong><\/td>New dosage forms, drug\u2011device combinations using novel technologies<\/td><\/tr>
\u2464 Medical Equipment<\/strong><\/td>Novel medical equipment and materials production\/processing<\/td><\/tr>
\u2465 Special Drugs<\/strong><\/td>Nucleic acid\u2011based drugs, radiopharmaceuticals, radioactive isotope diagnostics\/therapeutics<\/td><\/tr>
\u2466 Technology Transfer<\/strong><\/td>Transfer of innovative original drugs for domestic production<\/td><\/tr>
\u2467 Biomedical Materials<\/strong><\/td>Recombinant collagen\u2011based materials, biodegradable tissue regeneration materials, novel cavity materials<\/td><\/tr>
\u2468 Digital Health<\/strong><\/td>Internet + healthcare services, intelligent healthcare<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Impact<\/h2>\n\n\n\n
Stakeholder<\/th>Opportunity\/Requirement<\/th><\/tr><\/thead>
Foreign Investors<\/strong><\/td>Enhanced clarity and incentives for healthcare investments; tax benefits and streamlined approvals<\/td><\/tr>
Domestic Companies<\/strong><\/td>Increased competition but also partnership opportunities with global players<\/td><\/tr>
CROs\/Platforms<\/strong><\/td>Explicit encouragement of third\u2011party tech service platforms<\/td><\/tr>
Digital Health<\/strong><\/td>Formal recognition of internet\u2011based and intelligent healthcare services<\/td><\/tr>
Regulatory Timeline<\/strong><\/td>Effective Feb\u202f1\u202f2026; 30\u2011day transition period for compliance<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n